AUA 2021-The Impact of a Positive Family History of Hereditary Cancer-Associated Malignancies on Outcomes of Active Surveillance for Prostate Cancer

Dr. Keyan Salari, MD, PhD., urologic oncologist and Co-Director, Prostate Cancer Genetics Program at the Massachusetts General Hospital and Harvard Medical School discusses a presentation from the American Urological Association (AUA) 2021 Annual Meeting titled “The Impact of a Positive Family History of Hereditary Cancer-Associated Malignancies on Outcomes of Active Surveillance for Prostate Cancer. 

Keyan Salari, MD, PhD is a urologic oncologist at the Massachusetts General Hospital and Harvard Medical School. He is a urologic surgeon specialized in the treatment of genitourinary cancers using open, laparoscopic, and robotic surgery techniques. His research focuses on applying cancer genomics and computational biology methods to advance precision cancer medicine for genitourinary malignancies.

Dr. Salari is a faculty member of the Department of Urology and a Urologic Oncologist at the Massachusetts General Hospital Cancer Center. He graduated with honors from the University of California at Berkeley with a B.A. in molecular and cellular biology, where he was awarded the Spencer W. Brown Award and was a Howard Hughes Medical Institute Biology Fellow. He earned his MD and PhD in Genetics from Stanford University School of Medicine in the NIH Medical Scientist Training Program. He trained in General Surgery and Urology at the Massachusetts General Hospital and subsequently completed a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center.

Dr. Salari’s clinical practice focuses on the surgical treatment of urologic cancers with a particular emphasis on prostate cancer, kidney cancer, and testicular cancer. He serves as Co-Director of the Prostate Cancer Genetics Program, where families that may have a hereditary predisposition to prostate cancer are offered genetic testing, cancer screening, and support. His research interests focus on leveraging a variety of genomic technologies and computational biology methods to gain insight into the pathobiology of prostate cancer, with the goal of improving early detection of clinically significant prostate cancer and distinguishing indolent from aggressive disease to guide treatment decisions.